Journal article
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Blood, Vol.125(6), pp.992-998
02/05/2015
DOI: 10.1182/blood-2014-06-583369
PMCID: PMC4319239
PMID: 25422100
Abstract
Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients (n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group (SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P = .013, .042, and .0012) were associated with a poor EFS.
Details
- Title: Subtitle
- Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
- Creators
- Muhammad A Mir - Division of HematologyMatthew J Maurer - Biomedical Statistics and Informatics, andSteven C Ziesmer - Division of HematologySusan L Slager - Biomedical Statistics and Informatics, andThomas Habermann - Division of HematologyWilliam R Macon - Division of Hematopathology, Mayo Clinic, Rochester, MNBrian K Link - College of Medicine, University of Iowa, Iowa City, IASergei Syrbu - College of Medicine, University of Iowa, Iowa City, IAThomas Witzig - Division of HematologyJonathan W Friedberg - Wilmot Cancer Institute, University of Rochester, Rochester, NYOliver Press - Fred Hutchinson Cancer Center/South West Oncology Group Statistical Center, Seattle, WA; andMichael LeBlanc - Fred Hutchinson Cancer Center/South West Oncology Group Statistical Center, Seattle, WA; andJames R Cerhan - Division of Epidemiology, Mayo Clinic, Rochester, MNAnne Novak - Division of HematologyStephen M Ansell - Division of Hematology
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.125(6), pp.992-998
- Publisher
- United States
- DOI
- 10.1182/blood-2014-06-583369
- PMID
- 25422100
- PMCID
- PMC4319239
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Grant note
- CA11083 / NCI NIH HHS U10 CA020319 / NCI NIH HHS CA97274 / NCI NIH HHS P30 CA015083 / NCI NIH HHS P50 CA097274 / NCI NIH HHS CA20319 / NCI NIH HHS U10 CA032102 / NCI NIH HHS N01 CA038926 / NCI NIH HHS U10 CA180819 / NCI NIH HHS U10 CA011083 / NCI NIH HHS U10 CA180888 / NCI NIH HHS U10 CA038926 / NCI NIH HHS N01 CA032102 / NCI NIH HHS
- Language
- English
- Date published
- 02/05/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9984047691302771
Metrics
10 Record Views